We assessed the clinical impact of thrombelastography (TEG®) results (TEG® 5000, Haemonetics Corporation, Braintree, MA, USA) by measuring their ability to cause changes in a theoretical treatment plan and contribute to the understanding of haemostasis. We prospectively included paediatric intensive care unit (PICU) patients who had standard tests of haemostasis and TEG ordered and had an arterial catheter or extracorporeal access port in situ. Blood for standard tests and TEG was taken simultaneously. Independent of patient care, general patient information and results of standard laboratory tests were presented to five clinicians who were asked to document their theoretical treatment plan. Clinicians were then shown TEG results and asked if they caused a change in their plan, if they confirmed initial standard laboratory test results, if they enabled a better understanding of haemostasis and if they provided additional information. Inter-rater agreement between the clinicians was determined. Forty-two TEG results were obtained from 34 patients. Overall, the inclusion of TEG results led to a change in treatment plan in 97 of 207 occasions (47%), confirmed standard laboratory test results in 177 of 204 occasions (87%), enabled a better understanding of haemostasis in 140 of 204 occasions (69%) and provided additional information in 131 of 204 occasions (64%). Variation existed between clinicians, seemingly due to individual differences, with poor interrater agreement. We conclude that TEG results led to changes in treatment plans almost half the time, confirmed findings of standard tests and provided a better understanding of haemostasis, but randomised controlled trials are required to determine the role and influence of TEG results on patient outcome.
Haemostasis, especially in children, is complicated and can be misunderstood 1, 2 . Numerous tests of haemostasis are available and include 'standard' laboratory blood tests of coagulation (activated partial thromboplastin time [APTT], prothrombin time [PT] , International Normalized Ratio [INR], platelet count and fibrinogen level) as well as point-of-care tests such as the activated clotting time (ACT) and viscoelastic point-of-care tests (VETs) performed using viscoelastic haemostasis analysers. Assessing haemostasis in the complex patients of a paediatric intensive care unit (PICU), including cardiac surgical patients or patients receiving extracorporeal membrane oxygenation (ECMO) or continuous veno-venous haemofiltration (CVVH), presents further challenges due to underlying disease or the effects of surgery or treatment, including deliberate anticoagulation. These patients require haemostatic monitoring for a number of reasons, including the prevention of bleeding and thrombosis and for guidance on blood product administration. The goal of anticoagulation in ECMO for instance, is to manage thrombosis and bleeding, but achieving this balance is difficult and made more so by the current lack of a suitable test 3 . With the large number of tests available, it is possible that the most useful test is not being performed on the appropriate patients and the most relevant information is therefore not being considered in clinical management.
VETs are one of the potentially useful tests of haemostasis. VETs are global tests, analysing the function of both cellular and plasma components of whole blood by directly monitoring the mechanical properties of the clot as it forms and lyses [4] [5] [6] [7] [8] . By comparison, standard laboratory coagulation tests only provide a static, isolated measurement, and often only for plasma. Improved understanding of coagulation and the important role cellular elements play has highlighted the need for global tests such as VETs 9, 10 . In fact, numerous authors have claimed advantages of VETs over standard laboratory tests 11, 12 , especially in critically ill patients 8 , including the potential to pinpoint the causes of a coagulopathy, including hypercoagulability and thrombotic events 5, [13] [14] [15] , identifying fibrinolysis 3, 5, [13] [14] [15] [16] [17] , and assessing platelet activity and the relative contribution of platelets and fibrinogen [18] [19] [20] .
The TEG® 5000 Thrombelastograph® Hemostasis Analyzer System (Haemonetics Corporation, Braintree, MA, USA) is a commonly used device for performing VETs. When used in conjunction with the TEG Analytical Software (Haemonetics Corporation, Braintree, MA, USA) the TEG provides a graphical and numerical representation of the clot profile, including the time taken for the clot to first form and reach an amplitude of 2 mm (R time), the speed of formation (K and alpha [α] angle values), the strength of the clot (maximum amplitude, MA) and the rate of lysis (LY30). When used with the enzyme heparinase, the effect of heparin can also be separated out and measured. As a result, the TEG is sensitive to all the interacting cellular and plasma components that may affect the rate of formation, structure or stability of a clot.
The TEG clearly has a potential advantage over standard laboratory tests of haemostasis and the potential to add useful information to the clinical picture, but its specific value in guiding treatment in the PICU is unclear. The aim of this pilot study was to measure the potential clinical impact of TEG results on PICU patients by assessing if their incorporation into the theoretical treatment plans generated by a number of PICU clinicians would lead to a change in these plans, confirm the findings of the standard laboratory test results, enable a better understanding of patient haemostasis or provide additional useful information. In addition, we wanted to assess any variations that existed in the impact the TEG had between PICU clinicians.
Materials and methods
This was a prospective, non-interventional, observational study of the potential clinical impact of the TEG on the theoretical treatment plans developed for a group of PICU patients. The results of standard laboratory tests and general patient information were reviewed by a number of clinicians not involved in the patient's care, and independent of the patient's actual care, in order to determine a theoretical treatment plan. TEG results were then taken into consideration by each clinician and the clinicians reassessed their theoretical treatment plan and their own understanding of the patient's haemostatic status in light of the TEG's inclusion.
Subjects
Eligible participants were PICU patients who had any standard laboratory test of haemostasis as well as a VET ordered as part of their routine care and who had an arterial catheter or extracorporeal access port in situ in order to take blood samples. Patients were prospectively recruited from all eligible PICU patients when an appropriate member of the study team was present who could perform the TEG during the data collection phase (July to November 2010). Efforts were also made to minimise the inclusion of repeated tests from the same patient. Treating clinicians were not involved in the study. Hospital ethics committee approval was obtained and consent was not required (ref 30085A).
Sample collection
Blood samples, taken simultaneously for both standard laboratory tests and TEG analysis, were taken from the patient's arterial line or from the double-lumen access catheter of patients receiving CVVH or continuous venovenous plasmafiltration (CVVP). Dead space blood, up to 10 ml, was removed from all sample lines to avoid heparin contamination. Blood samples were initially collected into a plain syringe for the full blood count, coagulation tests and the TEG before being transferred to appropriate tubes. Samples for APTT, PT and fibrinogen were transferred into an S-Monovette® tube (Sarstedt, Australia) while blood for the full blood count (for platelet count, white blood cell count, haemoglobin and haematocrit) was transferred into an ethylenediaminetetraacetic acid tube and both tubes sent to the pathology laboratory for analysis. For TEG analysis, 1 ml of blood from the plain syringe was placed into a vial with a kaolin activator (#6300, Haemonetics Corporation) and gently mixed. Blood was also separately, and lastly, collected in a blood gas syringe to measure lactate and pH. Patients on ECMO, CVVH, CVVP or ventricular assist devices may also have had blood collected for ACT (Actalyke Mini II, Helena Laboratories, Beaumont, TX, USA) as per our unit's standard practices.
TEG performance
TEGs were performed by two authors or a trained ECMO nurse. The TEG analysers, located within PICU, were loaded with kaolin (K) and heparinase (KH) cups and set up and prepared for use prior to sample collection. Within four minutes of adding patient blood to the kaolin vial, 360 µl of blood was pipetted from the kaolin vial into the K and KH cups and the TEG started. The remaining 280 µl in the kaolin vial was kept with the TEG until completion of the test to help confirm the presence of, or in particular, the absence of a TEG-detected clot: if the TEG did not detect a clot, the blood in the vial was simply visually inspected to confirm that a clot had not formed in it either, which would confirm the TEG results and rule out a technical issue; and if the TEG did detect a clot, then this was also confirmed using the blood in the vial. TEGs were allowed to run for a minimum of one hour. TEG traces and the corresponding R time, K and α angles, MA and LY30 parameters were recorded for the K cup and the corresponding hR, hK, hα, hMA and hLY30 parameters were recorded for the KH cup. TEG traces and results were provided to treating clinicians with copies put aside with other patient information for later review by clinicians as part of the current study.
TEG classification
TEG traces and results were independently assessed by two authors using the following process: the K and KH traces were inspected and any problems noted; it was determined if a heparin effect was present (R-hR >0) (if no heparin effect was present, the K results were used for analysis; if a heparin effect was present, the KH trace was used), any other significant qualitative differences in K or KH traces were identified and noted and R time, α angle, MA and LY30 were assessed against expected ranges (R: 4 to 10 minutes, α: 47 o to 74 o , MA: 54 to 75 mm and LY30: 0% to 8% based on a modification of standard normal ranges [from Haemonetics] and institution-specific ones 21 , allowing for potential decreases in α angle and/or MA due to increased R time and considering a trace as normal if only one or two parameters were slightly [by ~ 1 unit] outside the expected range). The TEG results were then categorised as normal, having a heparin effect, haemorrhagic or thrombotic using one or more of the categories from the twelve detailed in Figure 1 .
Data collection
The following data was recorded for each patient at the time of blood sampling: age, weight, diagnosis, recent surgery (yes/no) (within last week approximately), number of days post-surgery, use of inotropes, bleeding state, presence of clots, the presence of drugs that could affect coagulation, the presence of heparin, whether the patient was receiving ECMO, support from a ventricular assist device, inhaled nitric oxide, high frequency oscillatory ventilation, CVVH or CVVP, whether the patient was ventilated, the fraction of inspired oxygen used and the reason for performing the TEG. Lactate, pH, haemoglobin, haematocrit, platelet count, white cell count, INR, APTT, PT, fibrinogen and ACT were recorded when available.
Clinician's assessment of the clinical impact of the TEG
After standard laboratory and TEG results had been collected, and independent of and subsequent to the patient's actual care, the data was presented to five clinicians who were not involved in the patient's care: a perfusionist, a PICU consultant, a PICU registrar, a PICU fellow and a haematologist working as a PICU registrar. Clinicians were first given the general patient information and only the results of the standard laboratory tests of haemostasis and were asked to document their theoretical patient treatment plan. Clinicians were then shown the full TEG results (with K and KH traces and accompanying quantitative results) and asked if the TEG results: • caused a change in the patient's treatment plan and if so how? • confirmed the standard laboratory test results? • enabled a better understanding of patient haemostasis? • provided additional useful information?
Clinicians were also asked to provide any other relevant comments and personal details (name, position, qualification and self-rating of TEG experience [low, medium or high]). The clinicians examined the data and returned their responses to the principal author at various stages between December 2010 and October 2012.
Agreement between clinicians
Clinicians were free to devise any theoretical treatment plan they thought appropriate as protocols were not used. We were therefore able to measure the variation in the approaches taken by the different clinicians in response to being presented with the TEG results. Formal inter-rater agreement between clinicians for each of the questions was conducted by statisticians using . Data for the question asking if the TEG results changed the theoretical treatment plan was also separately analysed by a statistician (using Stata) to identify any simple patterns of agreement or disagreement between the clinicians.
Results

Patient and TEG details
Forty-six sets of data were initially recorded from 35 patients. Four sets of data and one patient were of haemostasis on 140 of 204 occasions (69%) and provided additional information on 131 of 204 occasions 64% (Table  2) . Results did however vary widely between clinicians, but did not appear to be related to any particular patient or TEG characteristic. Overall clinical experience did seem to have some influence on the results however, with the haematologist rarely finding the TEG useful and the PICU consultant and haematologist typically least influenced by the TEG, reporting the lowest frequencies of changing treatment plans and gaining a better understanding, two of the three lowest occurrences of receiving additional information but the two highest rates of gaining confirmation of the standard test results from the TEG. By contrast, the perfusionist was the most likely (71%) to change plans based on TEG results and the least likely to find that the TEG confirmed standard test results (74%). Details of the specific actions proposed, as part of changes in theoretical treatment plans resulting from the inclusion of TEG results, are shown in Table 3 . It was common for more than one action to be suggested as part of the theoretical treatment plan, with two or more actions suggested on 56% of occasions. Most suggested changes related to blood product administration: the giving of fresh frozen plasma (39 occasions), platelets (25 occasions), cryoprecipitate (22 occasions) or packed red cells (two occasions). It was also common to suggest a decrease in heparin administration (28 occasions) after the TEG's inclusion. Variation existed between clinicians in their specific proposed changes based on the inclusion of TEG results, with the perfusionist prescribing much more fresh frozen plasma (18 of 39 total occasions), platelets (16 of 25 total occasions), cryoprecipitate (nine of 22 total occasions) and packed red blood cells (two of two total occasions) than the other clinicians. The perfusionist was also almost exclusively responsible for indicating repeat/additional testing was required (12 of 13 total occasions) with the haemoatologist responsible for the only other instance.
Inter-rater agreement
The results clearly indicate considerable variation between clinicians in all areas. Clinicians were only in complete agreement on whether the TEG led to a change in theoretical treatment plan on four occasions (9.5%)-three when no-one changed plans and once when all clinicians changed plans. It was much more common to have four of the five clinicians agree with each other. This occurred on 18 occasions (42.9%)-eight occasions where all except the haematologist (7) or PICU consultant (1) agreed that the inclusion of TEG results led to a change in theoretical treatment plan and on 10 occasions where four of the five clinicians did not change their theoretical treatment plan with the inclusion of the TEG (perfusionist on six occasions and the PICU consultant and PICU registrar on two occasions each). Formal interrater agreement for the question of changing the theoretical subsequently excluded-TEG traces from two patients were suspected of being conducted using a pair of kaolin cups rather than a kaolin and heparinase cup (with one pair of traces consisting of absent responses for both cups while the other pair of traces consisted of an unusual trace and a basically absent trace). One of these patients also had two sets of data collected at the latter stages of a prolonged admission and was excluded from a total of five sets of data in order to limit the number of within-patient repeated tests.
Ultimately, 42 sets of data were included in the analysis from 34 different patients ( Table 1 previous page). Eight patients had a second set of data recorded at an interval of between one and 18 days following their initial tests. Patient age varied from three days to 19 years and 18 days (median seven months and 16 days). Included patients had a range of diagnoses, including various congenital cardiac defects (ventricular septal defect [5] , pulmonary atresia [3] , myocarditis [2] , Fontan repair [2] , tricuspid atresia [2] , cardiomyopathy [2] , double outlet right ventricle with right ventricle-pulmonary artery conduit, Fallot's repair, Fallot's conduit and Jacobsen syndrome, Norwood repair, aortic atresia, total anomalous pulmonary venous drainage repair, subaortic stenosis and atrioventricular septal defect repair) as well as other illnesses (sepsis [2] , thrombotic thrombocytopenic purpura, burns, haemolytic uraemic syndrome, respiratory failure with Graves' disease, carnitine palmitoyltransferase 2 deficiency, toxic shock, acute renal failure and acute lymphoblastic leukaemia). Twenty-eight patients were receiving anticoagulants while ten patients were on ECMO at the time of testing. Patients were bleeding on 18 occasions and had clots noted on 11 occasions, with both bleeding and clots noted on five of these occasions. The patients with bleeding and/or clots displayed a wide range of TEG and standard test results.
Standard laboratory and TEG results are shown in Table 1 . A wide range of results was obtained with platelet counts ranging from 14 × 10 9 /l to 498 × 10 9 /l and APTTs ranging from 35 seconds to greater than 180 seconds. A heparin effect was detected on 31 occasions and ranged from 1.3 minutes to seven responses that were manually terminated after at least 90 minutes.
Most patients had multiple TEG categories recorded with the most common combination of TEG categories being '1 and 2' (heparin effect and normal) (n=8) and '1 and 4' (heparin effect and low clotting factors) (n=7). A 'reverse' heparin effect, defined as a negative value of (R -hR), was also detected on seven occasions; six were in post-cardiac surgical patients.
The clinical impact of the TEG
Overall, clinicians indicated that the addition of TEG results changed their theoretical treatment plan on 97 of 207 occasions (47%), confirmed the results of standard tests on 177 of 204 occasions (87%), enabled a better understanding The table details the individual, specific treatment actions that were included in clinician's theoretical treatment plans. FFP, fresh frozen plasma; TEG®, thrombelastography; *, other changes: change circuit and start aprotinin, lower threshold for platelet administration, change circuit, change anticoagulation on filter, stop prostacyclin, search for surgical bleeding, surgical revision due to bleeding and more weight for surgical management; PICU, paediatric intensive care unit. 
Discussion
Unfortunately, little published data exists to help determine the role of VET in the PICU. We conducted this pilot study to shed more light on a potential role of the TEG in the PICU and have presented 42 sets of TEG and standard laboratory test results from 34 patients who are representative of our PICU population and of the PICU patients for whom we believe TEG has a potential role. We were interested in assessing the clinical impact that TEG results can make on a patient's treatment. A new test, either a new technology or an existing test not currently used to its potential, may replace an existing test if the new test is better or performs equally well but has additional advantages (i.e. quicker, easier or cheaper). On the other hand, a new test may not be able to replace an existing test, either all or in part, but may provide different information and increase the overall level of knowledge. In the latter case, one would use only one test if it provided all of the relevant information, or the combination of tests if this is needed to provide all of the required information. In the current situation, we believe that the TEG is inherently different to standard tests of haemostasis and provides additional information, overlapping that provided by standard tests. This study intended to explore the relative value of the TEG.
While the basic quantitative results of the TEG and standard tests of haemostasis were obtained and could be compared to each other, we avoided the temptation to directly compare the simple, raw, numerical TEG results to standard tests of haemostasis as we feel their agreement is unimportant and it is the overall clinical utility, the 'impact', that is of more fundamental importance in the assessment of the clinical value of the TEG. In order to assess the TEG's clinical impact we had five clinicians review patient clinical status, incorporating standard laboratory test results and devise a theoretical treatment plan. We then assessed if the inclusion of TEG data led to a change in this plan. The clinicians were not asked to follow any particular protocol and were allowed to use various systems and approaches to devise a theoretical treatment plan and to subsequently incorporate the TEG results based on their own experience and understanding. This is consistent with our current practices. The addition of TEG results into the clinical picture did prove influential in developing treatment plans as their inclusion changed treatment plans on 71%, 44%, 53%, 60% and 7% of occasions for each of the five clinicians, respectively (47% overall).
We also asked the clinicians three additional questions to try and assess if the TEG results were largely duplicating (confirming) the information provided by the standard laboratory tests or if they provided a better understanding or additional information. If the addition of the TEG results simply confirmed those of the standard laboratory tests, then the value of the TEG is reduced; but if they added to understanding and provided extra value through additional information, then they have a potential place either alongside or instead of standard tests. Our results indicated that the TEG both supported and added to the standard tests with the TEG results confirming standard tests on 87% of all occasions, enabling a better understanding of haemostasis on 69% of all occasions and providing additional information on 64% of all occasions.
The findings for the question regarding TEG results confirming the results of standard tests of haemostasis were interesting, as it was the only question where the haematologist was not an outlier. The TEG results confirmed standard laboratory results for all clinicians in a high proportion (74% to 100%) of occasions. Although it was more common for clinicians to find the TEG confirmed standard tests than it was for them to change their theoretical treatment plan based on the TEG, the findings show that the use of the TEG results to confirm the standard test results is not mutually exclusive to using them to change treatment plans, as most clinicians commonly changed plans as well as indicating that the TEG results confirmed standard results. The exception is the haematologist, who probably has a higher level of expertise in this area and who indicated that the TEG primarily confirmed standard tests and rarely caused a change in their treatment plan or any other benefit. One explanation for this difference is that the clinicians interpreted this question slightly differently, with the results of the two questions for clinicians one to four indicating that while TEG results did confirm the standard laboratory results, they did more than just that and this caused the clinicians to change their treatment plans, or the clinicians may have been unsure with just the standard test results, and so acted conservatively and incorporated all available information into their plan when provided with additional information from the TEG. This is further supported by the specific findings that the TEG provided a better understanding and additional information for clinicians one to four on between 64% to 98% of occasions and 56% to 98% of occasions respectively. By comparison, the haematologist indicated that the inclusion of the TEG only provided a better understanding on one (2%) occasion and provided additional information on only 13% of occasions. The results from the haematologist suggest that they found standard tests to be adequate, with the TEG only adding to them on rare occasions. This level of expertise is likely to be uncommon in PICU however, and the other clinicians regularly found that the TEG provided additional information, confirmed standard tests and provided a better understanding of haemostasis as well as leading to a change in treatment plans Results for all questions varied significantly between clinicians with complete agreement rare and inter-rater agreement for all questions correspondingly poor. The variation between clinicians appeared to be caused largely by individual differences rather than patient characteristics, including the presence of bleeding or clots, TEG characteristics or level of TEG experience. We found the clinicians with the most overall experience, the PICU consultant and the haematologist, to be least convinced by the TEG, with the haematologist quite unconvinced. It could be speculated that the low incidence of changes by the haematologist was due to a greater understanding of the standard tests. It could therefore be suggested that an alternative to using additional tests of haemostasis such as the TEG would be to simply improve the level of knowledge of the standard tests amongst all users. On the other hand, if this higher level of expertise in the standard tests is unachievable, an additional test like the TEG could be useful even if it is to simply supplement standard tests. Our other clinicians regularly found that the TEG provided additional information, confirmed standard tests and provided a better understanding of haemostasis for instance.
We were unable to identify any studies similar to ours. VET use in PICU following cardiac surgery has been reported for guiding transfusions and predicting bleeding 18, [25] [26] [27] [28] [29] [30] [31] [32] . VETs have also been used in ECMO and mechanical circulatory support in PICU to guide product transfusion, measure platelet dysfunction, investigate thrombi, monitor and manage haemostasis in the presence of heparin and to detect residual heparinisation and hypercoagulability [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] , and could have a role in ECMO when it is desirable to minimise anticoagulation 44 . PICU-based studies of VETs have been performed in diabetic ketoacidosis 45 , snake bite 46 and to try and predict catheter-related thrombosis 47 but in few other situations. VETs have also been used in neonatal ICUs to assess coagulation 48 , predict neonatal sepsis 49 , to detect changes in coagulation due to persistent pulmonary hypertension and inhaled nitric oxide, 50 and to detect bleeding 51 . Clearly, more work is needed to clarify the role, if any, that VETs have in PICU.
There are a number of potential limitations in our study including the delay between data collection and publication, the use of a commercial product, study design, patient selection and technical issues. The elapsed time between data collection and publication is unfortunate but should not reduce the value of our findings as our practices are unchanged, the equipment is still current and widely used and no studies have addressed this issue in the meantime.
Another potential limitation in any study incorporating a commercial product like we have is the possibility that content, including design, data collection, analysis and manuscript preparation, were influenced by the supplier and/ or manufacturer but this is not a factor in the current study as we were self-funded and the supplier/manufacturer was not involved in these areas.
Our study design could have been stronger if clinicians were shown the TEG results for half of the patients before seeing the results of the standard laboratory tests of coagulation rather than all clinicians only seeing the TEG results after the standard test results. It may have also been ideal to have conducted specific education or employed a treatment protocol but our approach reflected current practices and knowledge levels in our PICU and allowed clinician differences to be explored. Unfortunately, the study design prevented us from quantifying the large disagreement between clinicians that was present in the standard treatment plans before the TEG was introduced in the same way we were able to after the introduction of the TEG results. Clinicians may have disagreed that the TEG caused a change in treatment plan because one clinician was already planning on doing what another clinician was motivated to change to only after the TEG information was presented. This may mean that some of the disagreement we measured related to the TEG may have already been present amongst the clinicians for the standard tests and may have artificially increased the observed level of disagreement. We were also not able to assess if the changed, 'ultimate' theoretical plan was a better treatment plan but our examination of the ultimate treatment plans made by the clinicians suggested that there were still wide variations between them even though some individual aspects were common. This heterogeneity may have resulted from the lack of protocol for the use of TEG, lack of protocol for general treatment, the fact that this was a 'thought' exercise rather than real, simple individual variation between clinicians or for other reasons. In addition, our study design would have been strengthened if our questions regarding TEG results enabling a better understanding of patient haemostasis and providing additional information sought more information on how this might have been achieved.
Another potential limitation of our study is that results may be different in a different group of patients. Patients were not always able to be recruited due to the absence, at times, of someone trained appropriately to perform a TEG but we feel that the patients were representative of PICU patients who require an assessment of haemostasis. In addition, we were not able to find any patient or TEG characteristics that appeared to influence our findings, although it would be ideal for further studies to try and identify specific patients, or patient groups, more likely to benefit from TEG.
Our study did not incur many technical issues related to the TEG. The TEG has been described as a moderately complex test requiring trained personnel 5, 6 and has some practical limitations itself, including the need for proper sample handling and susceptibility of the analyser to slippage, movement and vibration 8 . We managed this by having the TEG analysers located in a protected area within the clinical unit and only using a small group of trained staff to perform the TEGs, and feel that we succeeded as we encountered very few technical issues-two TEG traces were excluded because of a suspected user error and one where an 'eTest/ Disposable' error occurred in a K trace-compared to another study at our institution 21 , where technical issues occurred in 16 of 116 TEG samples (13.8%).
We took a broad, clinically relevant and practical approach in our examination of the TEG to attempt to assess its clinical 'impact' as measured by the ability of TEG results to cause a change in theoretical treatment plans of typical PICU patients. In addition, we tried to assess how TEG results interacted with the results of standard tests of haemostasis and whether the TEG added information not provided by these tests. Agreement between our clinicians was poor but this reflected individual differences and simply indicates heterogeneity rather than a failure of the TEG. Our results indicate that the TEG commonly added information and led to changes in almost half the treatment plans. In addition, the TEG also confirmed the findings of standard tests and provided a better understanding of haemostasis to our clinicians. Despite thromboelastography being around for many years and the subject of many studies, few studies are available to guide its use in PICU. The findings of this pilot study suggest that VETs probably do have a place in PICU but a randomised controlled trial that factors in differences between clinicians and compares PICU patients managed with standard tests alone to standard tests plus VET results and uses clinical outcome data as the gold standard should be conducted to determine the usefulness of TEG in this complex patient population.
